Ranbaxy consolidated net profit at Rs 117 cr in Q3
Ranbaxy Laboratories has improved its bottom line during the third quarter ended September 2009 despite fall in sales by 18 per cent. It earned a consolidated net profit of Rs 117 crore as against a net loss of Rs 395 crore during the corresponding period of last year. It’s consolidated net sales declined by 18 per cent to Rs 1,721 crore from Rs 1,888 crore.
Its standalone net sales, however, improved by 19.3 per cent to Rs 1,352 crore to Rs 1,133 crore in the corresponding period of last year. Trend in improvement of financial performance was aided by continued cost containment measures undertaken. The company returned to double-digit EBITDA margin, for the first time since Q2 ’08.
Comments